Concert Data in Alopecia Areata at the 2020 American Academy of Dermatology Virtual Annual Meeting

June 13th, 2020

Concert Pharmaceuticals released additional data from our Phase 2 clinical trial of the investigational agent CTP-543 in alopecia areata at the American Academy of Dermatology (AAD) 2020 Virtual Annual Meeting. The data analyses that we released build on the previously-reported Phase 2 primary efficacy analysis.

The results were selected as an oral presentation at the Late-Breaking Research Program at the in-person meeting, before it was converted to a virtual meeting due to the pandemic. The corresponding abstract was published by AAD in connection with the virtual meeting.

“We would like to thank the alopecia areata patients for their participation in this study, as well as the clinical investigators and research staff for their significant efforts to support the development of CTP-543,” said James Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals.
Concert’s press release on the new data analyses is here.

About AAD

The American Academy of Dermatology was founded in 1938. It is the largest, most influential and representative dermatology group in the United States. With a membership of more than 20,500 physicians worldwide, the AAD is committed to supporting and enhancing patient care for a lifetime of healthier skin, hair and nails.

Back to Top